CONTINUATION PAGE: STAY WITHIN MARGINS INDICATED 
Principal Investigator/Program Director (Last, first, middle): 
_ | 
Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, 
Prentice HG, Brenner MK. Endogenously generated activated killer cells circulate 
after autologous and allogeneic marrow transplantation but not after chemotheapy. I 
Blood 73:1351-1358, 1989. 
Heslop HE, Gottlieb DJ, Bianchi ACM, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, 
Brenner MK. In vivo induction of gamma interferon and tumor necrosis factor by 
interleukin-2 infusion following intensive chemotherapy or autologous marrow 
transplantation. Blood 74:1374-1380, 1989. 
Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner 
MK. Effects of recombinant interleukin-2 administration on cytotoxic function 
following high-dose chemo-radiotherapy for hematological malignancy. Blood 74:2335- ! 
2342, 1989. 
Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exley T, Brenner MK. Tumor necrosis 
factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol 
143:3828-3834, 1989. 
Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK. Requirements 
for the adoptive transfer of antibody responses to a priming antigen in man. 
J Immunol 144:541-547, 1990. 
Duncombe AS, Meager A, Prentice HG, Grundy JE, Heslop HE, Hoffbrand AV, Brenner MK. Gamma 
interferon and tumour necrosis factor production following bone marrow 
transplantation is augmented by exposure to marrow fibroblasts infected with CMV. 
Blood 76:1046-1053, 1990. 
Gottlieb DJ, Cryz SJ, Prentice HG, Duncombe AS, Brenner MK. Immunity against multiple 
Pseudomonas serotypes adoptively transferred to bone marrow transplant recipients. 
Blood 76:2470-2475, 1990. 
Heslop HE, Bianchi ACM, Cordingley FT, Turner M, Del Mel WCP, Hoffbrand AV, Brenner MK. 
Effects of a-interferon on autocrine growth factor loops in B lymphoprolif erative 
disorders. J Exp Med 172:1729-1734, 1990. 
Bello-Fernandez C, Bird C, Heslop HE, Gottlieb DJ , Reittie JE, Rill DM, Holland M, 
Prentice HG, Brenner MK. Homeostatic Action of IL-4 on Endogenous and Recombinant 
IL-2 Induced Activated Killer Cell Function. Blood 77:1283-1289, 1991. 
Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, 
Prentice HG, Hoffbrand AV, Brenner, MK. Possible mechanism of selective killing of 
myeloid leukemia blast cells by lymphokine-activated killer cells. Blood 77:1996- 
2001, 1991. 
Brenner M, Mirro J Jr, Hurwitz C, Santana V, Ihle J, Krance R, Ribeiro R, Roberts WM, 
Mahmoud H, Schell M, Garth K. Autologous bone marrow transplant for children with 
AML in first complete remission: Use of marker genes to investigate the biology of 
marrow reconstitution and the mechanism of relapse. Human Gene Ther 2:137-159, 1991. 
Rill DR, Buschle M, Foreman NK, Bartholomew C, Moen RC, Santana VM, Ihle JN, Brenner MK. 
Retrovirus mediated gene transfer as an approch to analyze neuroblastoma relapse 
after autologous marrow transplantation. Human Gene Ther 3:129-136, 1992. 
Duncombe AS, Grundy JE, Oblakowski P, Prentice HG, Gottlieb DJ, Roy DM, Reittie JE, Bello- 
Fernandez C, Hoffbrand AV, Brenner MK. Bone marrow transplant recipients have 
defective MHC unrestricted cytotoxic responses against cytomegalovirus in comparison 
with Epstein-Barr virus: the importance of target cell expression of lymphocyte- 
function-associated antigen (LFA1). Blood 79:3059-3066, 1992. 
Rencher SD, Hanif I, Heslop HE, Turner V, Brenner MK, Hurwitz JL. Reconstitution of the 
T-cell receptor a(3 repertoire in recipients of allogeneic bone marrow transplant. 
Bone Marrow Transplant 10:521-527, 1992. 
Buschle M, Campana D, Carding VR, Hoffbrand AV, Brenner MK. Interferon-y inhibits 
apoptosis in B cell chronic lymphocytic leukemia. J Exp Med 177:213-218, 1993. 
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene-marking 
to trace origin of relapse after autologous bone marrow transplantation. Lancet 
341:85-86, 1993. 
PHS 398 (Rev. 9/91) Page 
Number pages.(»osficutively at the bottom throughout the application. Do not use suffixes such ^ ffiiffirVh inan t DNA RcSCSTCh, Volume 18 
